Zika Virus Infection's Neonatal and Pediatric Consequences in French Department of America

Inclusion Criteria

• •Cohort 1:
• •1. symptomatic acute infection ZIKV has been confirmed in mother by RT-PCR in blood or urine or serology neutralization or other specific technique that would be validated and become available before the end of the epidemic period OR
• •2. Mother enrollment in ZIKA DFA FE study (Module 1) OR
• •3. ZIKA seroconversion documented during pregnancy, especially objectified in the pregnant women's monitoring in the modules 3 and 4 of ZIKA-DFA-FE study AND
• •4. No birth defects in newborn at birth (see Appendix 5).
• •1. Mother enrollment in ZIKA DFA FE study (Module 2) OR
• •2. Children born from mothers enrolled in ZIKA-DFA-FE study (modules 3 and 4) and having congenital abnormalities discovered at birth
• •And having at least one of these following abnormalities:
• •Head circumference (HC) \< 2 SD, using Intergrowth curves:
• •(http://intergrowth21.ndog.ox.ac.uk/Newborn/en/ManualEntry) Presence of birth defects in newborn at birth (see Annex 5)
• •1. Mother enrollment in ZIKA DFA FE study (Module 3 \&4)
• •2. Mother's ZIKV seronegative in childbirth
• •3. No birth defects in newborn at birth (see Appendix 5).